Olaparib monotherapy is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/04/2019|
|Rapid review completed||09/05/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||15/05/2019|
|Pre-submission consultation with Applicant||15/07/2019|
|Submission received from Applicant||10/10/2019|
|Preliminary review sent to Applicant||08/01/2020|
|NCPE assessment re-commenced||24/01/2020|
|Factual accuracy sent to Applicant||09/03/2020|
|NCPE assessment re-commenced||13/03/2020|
|NCPE assessment completed||30/03/2020|
|NCPE assessment outcome||Following assessment of the Applicant’s submission, the NCPE recommends that olaparib (Lynparza®) for this indication not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.